371 related articles for article (PubMed ID: 19901119)
1. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
Treviño LR; Shimasaki N; Yang W; Panetta JC; Cheng C; Pei D; Chan D; Sparreboom A; Giacomini KM; Pui CH; Evans WE; Relling MV
J Clin Oncol; 2009 Dec; 27(35):5972-8. PubMed ID: 19901119
[TBL] [Abstract][Full Text] [Related]
2. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
[TBL] [Abstract][Full Text] [Related]
3. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.
Ramsey LB; Bruun GH; Yang W; Treviño LR; Vattathil S; Scheet P; Cheng C; Rosner GL; Giacomini KM; Fan Y; Sparreboom A; Mikkelsen TS; Corydon TJ; Pui CH; Evans WE; Relling MV
Genome Res; 2012 Jan; 22(1):1-8. PubMed ID: 22147369
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide study of methotrexate clearance replicates SLCO1B1.
Ramsey LB; Panetta JC; Smith C; Yang W; Fan Y; Winick NJ; Martin PL; Cheng C; Devidas M; Pui CH; Evans WE; Hunger SP; Loh M; Relling MV
Blood; 2013 Feb; 121(6):898-904. PubMed ID: 23233662
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
Yang JJ; Cheng C; Yang W; Pei D; Cao X; Fan Y; Pounds SB; Neale G; Treviño LR; French D; Campana D; Downing JR; Evans WE; Pui CH; Devidas M; Bowman WP; Camitta BM; Willman CL; Davies SM; Borowitz MJ; Carroll WL; Hunger SP; Relling MV
JAMA; 2009 Jan; 301(4):393-403. PubMed ID: 19176441
[TBL] [Abstract][Full Text] [Related]
7. Delayed Methotrexate Elimination after Administration of a Medium Dose of Methotrexate in a Patient with Genetic Variants Associated with Methotrexate Clearance.
Tatebe Y; Kanamitsu K; Kanzaki H; Ishida H; Fujiwara K; Washio K; Kitamura Y; Sendo T; Shimada A; Tsukahara H
Acta Med Okayama; 2020 Dec; 74(6):545-550. PubMed ID: 33361876
[TBL] [Abstract][Full Text] [Related]
8. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
9. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
[TBL] [Abstract][Full Text] [Related]
10. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
[TBL] [Abstract][Full Text] [Related]
11. Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia.
Wang SM; Zeng WX; Wu WS; Sun LL; Yan D
Leuk Res; 2018 Feb; 65():61-66. PubMed ID: 29306656
[TBL] [Abstract][Full Text] [Related]
12. Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia.
Cheng Y; Chen MH; Zhuang Q; Lin BJ; Chen YY; Yang L; Liu MB; Que WC; Qiu HQ
Pediatr Blood Cancer; 2021 May; 68(5):e28858. PubMed ID: 33501733
[TBL] [Abstract][Full Text] [Related]
13. Effects of
Yang FF; Xue TL; Gao C; Wu Y; Lin W; Li J; Zhang RD; Zheng HY; Liu SG
Pharmacogenomics; 2022 Oct; 23(15):821-834. PubMed ID: 36193736
[No Abstract] [Full Text] [Related]
14. Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma.
Schulte RR; Choi L; Utreja N; Van Driest SL; Stein CM; Ho RH
Clin Transl Sci; 2021 Jan; 14(1):343-353. PubMed ID: 32961024
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters.
Hu YH; Zhou L; Wang SS; Jing X; Guo HL; Sun F; Zhang Y; Chen F; Xu J; Ji X
Curr Pharm Des; 2019; 25(6):627-634. PubMed ID: 30931851
[TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
Rau T; Erney B; Göres R; Eschenhagen T; Beck J; Langer T
Clin Pharmacol Ther; 2006 Nov; 80(5):468-76. PubMed ID: 17112803
[TBL] [Abstract][Full Text] [Related]
17. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.
Bhojwani D; Sabin ND; Pei D; Yang JJ; Khan RB; Panetta JC; Krull KR; Inaba H; Rubnitz JE; Metzger ML; Howard SC; Ribeiro RC; Cheng C; Reddick WE; Jeha S; Sandlund JT; Evans WE; Pui CH; Relling MV
J Clin Oncol; 2014 Mar; 32(9):949-59. PubMed ID: 24550419
[TBL] [Abstract][Full Text] [Related]
19. SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy.
Eldem İ; Yavuz D; Cumaoğullari Ö; İleri T; Ünal İnce E; Ertem M; Doğanay Erdoğan B; Bindak R; Özdağ H; Şatiroğlu-Tufan NL; Uysal LZ
J Pediatr Hematol Oncol; 2018 Jul; 40(5):e289-e294. PubMed ID: 29683944
[TBL] [Abstract][Full Text] [Related]
20. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.
Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V
Pharmacogenet Genomics; 2014 Oct; 24(10):514-21. PubMed ID: 25098908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
